Tocvan Drills 15.3 meters of 1.1 g/t Au in New 4-Trench Extension Defines new mineralized trend over a 500 meter strike at Pilar

CSE:TOC, TocVan Ventures, gold, mexico

Tocvan Ventures Corp. (CSE:TOC) (CNSX:TOC.CN) (“Tocvan” or the “Corporation”) is pleased to announce results for the next four drill holes from its Phase II drill program (the “Program”) at the Pilar Gold-Silver Project in Sonora, Mexico. A Phase II drill program was completed in June with over 3,500 meters of reverse circulation (RC) drilling in twenty (20) drill holes. Results for four drill holes from the 4-Trench target area are included in this release, highlighted by drill hole JES-21-53 which returned 15.3 meters at 1.1 g/t Au. The results from 4-Trench have defined a new mineralized trend 500 meters long adjacent to the established Main Zone (Figure 1). Three (3) drill holes from new target areas are pending results. read more

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

Additionally, second patent award received in Japan
Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that dosing has been completed in its second human clinical study of 2021. read more

NexGen Announces Commencement of 2021 Field and Regional Exploration Drilling Programs at the Rook I Property

T.NXE, NexGen, uranium
Figure 1: Rook I Property 2021 Exploration Target Areas (CNW Group/NexGen Energy Ltd.)

NexGen Energy Ltd. (“NexGen” or the “Company”) (TSX: NXE) (NYSE: NXE) (ASX: NXG) is pleased to announce commencement of field programs focused on detailed geotechnical site confirmation studies on the Project and regional exploration drilling at the 100% owned, Rook I property (the “Property”), in the Athabasca Basin, Saskatchewan. read more

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved
Lexaria Bioscience
  read more

Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects
Lexaria Bioscience
DrugCmax* % Improvement
(ng/mL)
Control
(ng/mL)
AUClast** % Improvement
(hr∙ng/mL)
Control
(hr∙ng/mL)
Colchicine31.97
91%
(p=0.0005)
16.73104.43
167%
(p=0.0028)
38.97

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. read more

Gran Colombia Announces Second Quarter 2021 Production and Webcast; Provides Details of Forthcoming Repayment of Its Gold Notes; Declares Monthly Dividend to be Paid on August 16, 2021

Gran Colombia Gold Corp. (TSX: GCM; OTCQX: TPRFF) announced today that it produced a total of 16,789 ounces of gold at its Segovia Operations in June 2021 bringing the total gold production for the second quarter of 2021 to 52,198 ounces compared with 44,377 ounces from Segovia in the second quarter of 2020. The Company also produced 54,573 ounces of silver at Segovia in the second quarter of 2021, up from 41,342 ounces of silver in the second quarter last year. For the first half of 2021, Segovia’s gold and silver production totalled 101,256 ounces and 111,888 ounces, respectively, up from 94,723 ounces of gold and 87,260 ounces of silver in the first half of 2020. read more

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada’s National Research Council

VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada’s premier federally funded research organization, the National Research Council (“NRC”). read more

NexGen Community Update:

Signs Impact Benefit Agreement with Buffalo River Dene Nation, Signs Mutual Benefit Agreement with Birch Narrows Dene Nation, Appoints Community Based Project Liaison Manager, and The Court of Queen’s Bench for Saskatchewan Dismisses MN-S Application,
T.NXE, NexGen, uranium

NexGen Energy Ltd. (“NexGen” or the “Company”) (TSX: NXE) (NYSE MKT: NXE) is pleased to announce the signing of an Impact Benefit Agreement (“IBA”) with the Buffalo River Dene Nation (“BRDN”), and the signing of a Mutual Benefit Agreement (“MBA”) with the Birch Narrows Dene Nation (“BNDN”), covering all phases of the Rook I Project (“Rook I” or the “Project”), which hosts the 100% owned Arrow uranium deposit. read more

Lexaria Receives Patent Protection in Japan

New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia
Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces an additional expansion of its intellectual property portfolio with its first-ever patent granted in Japan. read more

Magazine Plus by WEN Themes